Please use this identifier to cite or link to this item:
Title: A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.
Authors: Sbarrato, T.
Horvilleur, E.
Pöyry, T.
Hill, K.
Chaplin, L. C.
Spriggs, R. V.
Stoneley, M.
Wilson, L.
Jayne, S.
Vulliamy, T.
Beck, D.
Dokal, I.
Dyer, M. J.
Yeomans, A. M.
Packham, G.
Bushell, M.
Wagner, S. D.
Willis, A. E.
First Published: 2-Jun-2016
Publisher: Nature Publishing Group for Associazione Differenziamento e Morte Cellulare
Citation: Cell Death and Disease (2016) 7, e2249;
Abstract: We have used polysome profiling coupled to microarray analysis to examine the translatome of a panel of peripheral blood (PB) B cells isolated from 34 chronic lymphocytic leukaemia (CLL) patients. We have identified a 'ribosome-related' signature in CLL patients with mRNAs encoding for ribosomal proteins and factors that modify ribosomal RNA, e.g. DKC1 (which encodes dyskerin, a pseudouridine synthase), showing reduced polysomal association and decreased expression of the corresponding proteins. Our data suggest a general impact of dyskerin dysregulation on the translational apparatus in CLL and importantly patients with low dyskerin levels have a significantly shorter period of overall survival following treatment. Thus, translational dysregulation of dyskerin could constitute a mechanism by which the CLL PB B cells acquire an aggressive phenotype and thus have a major role in oncogenesis.
DOI Link: 10.1038/cddis.2016.148
ISSN: 2041-4889
eISSN: 2041-4889
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: This work is licensed under a Creative Commons Attribution 4.0 International License.
Description: Supplementary Information accompanies this paper on Cell Death and Disease website
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
cddis2016148a.pdfPublished (publisher PDF)3.36 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.